Miyake Hiroshi, Iizawa Yuji, Baba Masanori
Division of Human Retroviruses, Center for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Kagoshima 890-8520, USA.
J Clin Microbiol. 2003 Jun;41(6):2515-21. doi: 10.1128/JCM.41.6.2515-2521.2003.
CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1) is a major viral population that is transmitted by sexual intercourse and that replicates in infected individuals during the asymptomatic stage of HIV-1 infection, suggesting that agents effective against R5 HIV-1 can be expected to prevent viral transmission and delay disease progression. However, R5 HIV-1 is unable to replicate in human T-cell lines, which is an apparent obstacle to efficient and reliable susceptibility tests of compounds for their activities against R5 HIV-1. To establish a simple and rapid assay system for the monitoring of R5 HIV-1 replication and drug susceptibility, we have established a novel reporter T-cell line, MOCHA (which represents MOLT-4 cells stably expressing CCR5 and carrying the HIV-1 long terminal repeat-driven secretory alkaline phosphatase). Cells of this cell line express CD4, CXCR4, and CCR5 on their surfaces and secrete human placental alkaline phosphatase into the culture supernatants during HIV-1 infection. MOCHA cells proved to be highly permissive for the replication of R5 HIV-1 as well as CXCR4-using (X4) HIV-1, and the alkaline phosphatase activity increased in parallel with increasing HIV-1 p24 antigen levels in the culture supernatants. When HIV-1 reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors, including the CCR5 antagonist TAK-779 and the CXCR4 antagonist AMD3100, were examined for their inhibitory effects on R5 and X4 HIV-1 replication in MOCHA cells, the antiviral activities of these compounds were found to be almost identical to those previously reported in peripheral blood mononuclear cells. Thus, MOCHA cells are an extremely useful tool for detection of R5 and X4 HIV-1 replication and drug susceptibility tests.
利用CCR5的1型人类免疫缺陷病毒(HIV-1)是一种主要的病毒群体,可通过性交传播,并在HIV-1感染的无症状阶段在受感染个体中复制,这表明有望通过有效对抗R5 HIV-1的药物来预防病毒传播并延缓疾病进展。然而,R5 HIV-1无法在人类T细胞系中复制,这显然阻碍了对化合物抗R5 HIV-1活性进行高效可靠的药敏试验。为建立一个简单快速的检测系统来监测R5 HIV-1的复制和药敏情况,我们建立了一种新型报告T细胞系MOCHA(代表稳定表达CCR5并携带HIV-1长末端重复序列驱动的分泌性碱性磷酸酶的MOLT-4细胞)。该细胞系的细胞在其表面表达CD4、CXCR4和CCR5,并在HIV-1感染期间将人胎盘碱性磷酸酶分泌到培养上清液中。事实证明,MOCHA细胞对R5 HIV-1以及利用CXCR4的(X4)HIV-1的复制具有高度的易感性,并且碱性磷酸酶活性随着培养上清液中HIV-1 p24抗原水平的升高而平行增加。当检测HIV-1逆转录酶抑制剂、蛋白酶抑制剂和进入抑制剂(包括CCR5拮抗剂TAK-779和CXCR4拮抗剂AMD3100)对MOCHA细胞中R5和X4 HIV-1复制的抑制作用时,发现这些化合物的抗病毒活性与先前在外周血单核细胞中报道的活性几乎相同。因此,MOCHA细胞是检测R5和X4 HIV-1复制及药敏试验的极其有用的工具。